[Hypertension as a part of metabolic cardiovascular syndrome]
- PMID: 1948918
[Hypertension as a part of metabolic cardiovascular syndrome]
Abstract
Hypertension is only one of several cardiovascular risk factors that tend to cluster. Hypertension is associated with glucose intolerance, hyperinsulinemia, decreased HDL-cholesterol, high triglycerides and decreased fibrinolytic activity. One possible link is insulin resistance, which also links hypertension to obesity and diabetes mellitus type II. The authors review the literature and discuss clinical and therapeutic implications in the treatment of hypertension. Since the hypertensive patient may have an unfavourable cardiovascular risk profile, a non-pharmacological approach is essential in the treatment. Furthermore, if antihypertensive agents have to be used, metabolic side effects should be monitored closely, since they may reduce the beneficial effects of the blood pressure reduction on the cardiovascular risk profile.
Similar articles
-
Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.Pharmacol Ther. 2008 Mar;117(3):354-73. doi: 10.1016/j.pharmthera.2007.10.004. Epub 2007 Dec 14. Pharmacol Ther. 2008. PMID: 18215759 Review.
-
The sympathetic nervous system may modulate the metabolic cardiovascular syndrome in essential hypertension.J Cardiovasc Pharmacol. 1992;20 Suppl 8:S32-9. J Cardiovasc Pharmacol. 1992. PMID: 1283768 Review.
-
Diabetes and hypertension: a review.Prim Care. 1991 Sep;18(3):509-24. Prim Care. 1991. PMID: 1658839 Review.
-
Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors.Int J Obes (Lond). 2007 Jun;31(6):927-32. doi: 10.1038/sj.ijo.0803543. Epub 2007 Feb 13. Int J Obes (Lond). 2007. PMID: 17264851
-
[Insulin resistance and arterial hypertension].Herz. 1995 Feb;20(1):16-32. Herz. 1995. PMID: 7713473 Review. German.
Cited by
-
Design, Synthesis and Evaluation of Novel 2-Hydroxypyrrolobenzodiazepine-5,11-dione Analogues as Potent Angiotensin Converting Enzyme (ACE) Inhibitors.Molecules. 2017 Nov 3;22(11):1739. doi: 10.3390/molecules22111739. Molecules. 2017. PMID: 29099799 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical